Overall, 96.7% (95% CI 94.5–98.9) of patients with a low uPA/PAI-1-status remained recurrence-free at five years and 87.2% (95% CI 84.1–90.3) with a high uPA/PAI-1 status even after adjustment to tumour size, nodal status, grading, steroid hormone receptor (sHR) status and HER2 status (adjusted HR 2.6, 95% CI 1.29–5.23). This evidence concerns the gene ERBB2 and neoplasm.